Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
24. 58
-0.03
-0.12%
$
144.12B Market Cap
14.55 P/E Ratio
1.68% Div Yield
47,247,571 Volume
1.43 Eps
$ 24.61
Previous Close
Day Range
24.45 24.78
Year Range
20.92 31.54
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 10 days

Summary

PFE closed today lower at $24.58, a decrease of 0.12% from yesterday's close, completing a monthly increase of 4.42% or $1.04. Over the past 12 months, PFE stock lost -8.11%.
PFE pays dividends to its shareholders, with the most recent payment made on Jun 13, 2025. The next announced payment will be in In 1 month on Sep 02, 2025 for a total of $0.43.
The last earnings report, released on Apr 29, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.12%, based on the last three reports. The next scheduled earnings report is due on Jul 28, 2025.
Pfizer Inc. has completed 6 stock splits, with the recent split occurring on Nov 17, 2020.
The company's stock is traded on 16 different exchanges and in various currencies, with the primary listing on NYSE (USD).

PFE Chart

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.

Cnbc | 15 hours ago
I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk

I Sold Pfizer at a 13% Loss – Here's Why I'm Choosing Stability Over Risk

A Reddit poster took a big loss on Pfizer. They needed to dump some shares because they occupied a huge chunk of their portfolio.

247wallst | 19 hours ago
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price

The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.

Wsj | 21 hours ago

Pfizer Inc. (PFE) FAQ

What is the stock price today?

The current price is $24.58.

On which exchange is it traded?

Pfizer Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is PFE.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.68%.

What is its market cap?

As of today, the market cap is 144.12B.

When is the next earnings date?

The next earnings report will release on Jul 28, 2025.

Has Pfizer Inc. ever had a stock split?

Pfizer Inc. had 6 splits and the recent split was on Nov 17, 2020.

Pfizer Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Albert Bourla CEO
NYSE Exchange
717081103 Cusip
US Country
81,000 Employees
25 Jul 2025 Last Dividend
17 Nov 2020 Last Split
13 Aug 2012 IPO Date

Overview

Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849. Based in New York, New York, Pfizer has established itself as a leader in the discovery, development, manufacture, marketing, distribution, and sale of innovative biopharmaceutical products. Serving a wide range of therapeutic areas, Pfizer's portfolio includes medicines and vaccines that address a variety of health concerns, from cardiovascular metabolic conditions and infectious diseases to chronic immune and inflammatory diseases. The company has a significant global footprint, operating across the United States, Europe, and other international markets, catering to wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and more. Through strategic collaboration agreements with entities like Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE, Pfizer continues to lead in the development of medical breakthroughs for unmet medical needs.

Products and Services

  • Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands: Targeting cardiovascular metabolic, migraine, and women's health, these products offer innovative treatments in their respective therapeutic areas.
  • Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands: Focused on infectious diseases with unmet medical needs, including vaccines for various age groups and conditions.
  • Comirnaty and Paxlovid brands: At the forefront of COVID-19 prevention and treatment, offering some of the earliest and most effective vaccines and antiviral treatments against the virus. Furthermore, Pfizer is exploring potential future mRNA and antiviral products.
  • Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands: Offering biosimilars and original treatments for chronic immune and inflammatory diseases, showing Pfizer’s commitment to broadening access to critical medication.
  • Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands: Addressing rare and severe conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease with cutting-edge biopharmaceutical treatments.
  • Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands: Including sterile injectable and anti-infective medicines that play a vital role in treating various infections and conditions.
  • Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands: A comprehensive list of biologics, small molecules, immunotherapies, and biosimilars for treating cancer and other severe diseases, showcasing Pfizer’s extensive contribution to oncology and other advanced therapeutic areas.
  • Contract Manufacturing: In addition to its extensive pharmaceutical product lineup, Pfizer is also involved in the contract manufacturing business, leveraging its vast infrastructure and expertise to produce medicines for other entities.

Contact Information

Address: 235 East 42nd Street
Phone: 212 733 2323